使用患者登记册进行下垂体疾病过渡研究的可行性:一项EuRREB二次调查
Savi Shishkov1, Violeta Iotova2,3, Iris Pelsma4
1Department of Endocrinology, Medical University of Varna, Clinic of Endocrinology, UMHAT "Sveta Marina", Varna, Bulgaria.
Endocrine connections
|November 14, 2025
概括
这项研究使用注册表评估了罕见垂体疾病的过渡护理,发现了高随访但不一致的过渡计划和患者报告的结果. 罕见疾病注册表有助于了解过渡障碍.
科学领域:
- 内分泌学 在内分泌学.
- 罕见疾病 罕见疾病
- 患者过渡护理 患者过渡护理
背景情况:
- 罕见疾病登记册对于了解罕见内分泌条件下的自然历史和过渡过程至关重要.
- 下垂体疾病是罕见内分泌疾病中的一个重要领域,需要专注的过渡研究.
研究的目的:
- 评估欧洲罕见内分泌和骨疾病注册表 (EuRREB) 的可行性,用于垂体疾病过渡研究.
- 在欧洲罕见内分泌疾病参考网络 (Endo-ERN) 参考中心 (RCs) 管理的过渡年龄下垂体患者的特征.
主要方法:
- 纳入标准:14-24岁的患者,在EuRREB核心注册表中被诊断患有垂体病.
- 医生们完成了一项关于过渡方面的二次调查.
- 使用了描述性统计和非参数分析 (克鲁斯卡尔-瓦利斯,曼-惠特尼).
主要成果:
- 98/106名符合条件的患者确诊;分析了来自5个国家的6个RC的79名患者的数据.
- 91%的患者仍在积极护理中,其中36.7%转移到成人护理中,通常在18岁左右.
- 记录的转移计划 (13.9%) 和患者报告的结果 (13.5%) 被不一致地收集,发现了与护理或患者相关的挑战.
结论:
- 这项研究提供了对Endo-ERNRCs罕见垂体疾病的护理过渡的初步特征.
- 观察到大量的患者随访,但使用过渡计划和患者报告的结果措施 (PROM) 是不一致的.
- 罕见疾病注册表是了解过渡过程和识别罕见疾病障碍的宝贵工具.
相关概念视频
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K


